FORT LAUDERDALE, FL – FEBRUARY 13, 2020 – ImmunSYS announced today that Charles Link, M.D., President and Chief Medical Officer, presented this week on February 11th at the 2020 BIO CEO & Investor Conference in New York.
Now in its 22nd year, the conference is one of the largest independent investor conferences focused on established and emerging publicly traded and select private biotech companies. It involves two days of partnering meetings with institutional and early-stage investors, industry analysts, and senior biotechnology executives, in one location.
To learn more about the meeting, please visit the BIO website: https://www.bio.org/events/bio-ceo-investor-conference
To view Dr. Link’s presentation, please click on the document below.
ImmunSYS, Inc. is a clinical stage biopharmaceutical company focused on the development of innovative cancer immunotherapy products to improve the lives of patients with late-stage metastatic prostate cancer and other adenocarcinomas. The company’s platform technology, YourVaccx™ utilizes a novel combination of the ANTIGENerator™ energy delivery system for controlled cell lysis and a proprietary triple-component immunotherapeutic drug.
This new immunotherapy therapy is designed to empower the immune system to recognize and selectively attack cancer cells. The company is initially developing the new cancer therapy for the treatment of metastatic prostate cancer, with a pipeline of additional development programs for other metastatic solid tumor cancers. For more information about the company and its programs, visit http://www.immunsys.com/.
This news release contains forward-looking statements. Forward-looking statements can be identified by words such as “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and other words and terms of similar meaning. The forward-looking statements contained in this news release include, but are not limited to, statements relating to future clinical results and the effectiveness of the company’s therapies. These forward-looking statements are subject to risks, uncertainties and other factors. Accordingly, actual results may differ significantly from those projected in the forward-looking statements contained herein. Readers should not place undue reliance on these forward-looking statements. The forward-looking statements included in this new release are made only as of the date hereof, and the company does not undertake any obligation to update any forward-looking statements to reflect subsequent events or circumstances, except as required by applicable law.
Joseph Gerardi, 518-796-6110
Executive Vice President, Chief Financial Officer